Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gernot Rassner

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
International Journal of Dermatology|December 13, 2005
Bullous variant of Sweet's syndromeSusanne Voelter-Mahlknecht, Jürgen Bauer, Gisela Metzler, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 27, 2003
"Functional" surgery in subungual melanomaMatthias Moehrle, Silke Metzger, Wilfried Schippert, et al.
Psychotherapie, Psychosomatik, Medizinische Psychologie|June 19, 2003
[Psychosocial burden and subjective experience of melanoma patients in the ambulant follow-up]Andreas Blum, Dorothea Blum, Waltraud Stroebel, et al.
Journal of the American Academy of Dermatology|July 2, 2003
Ulcerated epithelioid hemangioendothelioma of the foot in childhoodAndrea Forschner, Dieter Harms, Gisela Metzler, et al.
Cancer|March 26, 2003
Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patientsClaus Garbe, Ulrike Leiter, Ulf Ellwanger, et al.
European Journal of Pediatrics|November 26, 2002
Molecular diagnostics facilitate distinction between lethal and non-lethal subtypes of junctional epidermolysis bullosa: a case report and review of the literatureJürgen Bauer, Hauke Schumann, Karsten Sönnichsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cellsAnja Ulmer, Oleg Schmidt-Kittler, Jörg Fischer, et al.
Journal of the American Academy of Dermatology|January 31, 2006
Metastatic glucagonoma: treatment with liver transplantationPeter Radny, Thomas Kurt Eigentler, Karsten Soennichsen, et al.
Experimental Dermatology|June 26, 2003
Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanomaFriedegund Meier, Ulrich Caroli, Kapaettu Satyamoorthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategyClaus Garbe, Andrena Paul, Hanna Kohler-Späth, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
International Journal of Dermatology|December 13, 2005
Bullous variant of Sweet's syndromeSusanne Voelter-Mahlknecht, Jürgen Bauer, Gisela Metzler, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 27, 2003
"Functional" surgery in subungual melanomaMatthias Moehrle, Silke Metzger, Wilfried Schippert, et al.
Psychotherapie, Psychosomatik, Medizinische Psychologie|June 19, 2003
[Psychosocial burden and subjective experience of melanoma patients in the ambulant follow-up]Andreas Blum, Dorothea Blum, Waltraud Stroebel, et al.
Journal of the American Academy of Dermatology|July 2, 2003
Ulcerated epithelioid hemangioendothelioma of the foot in childhoodAndrea Forschner, Dieter Harms, Gisela Metzler, et al.
Cancer|March 26, 2003
Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patientsClaus Garbe, Ulrike Leiter, Ulf Ellwanger, et al.
European Journal of Pediatrics|November 26, 2002
Molecular diagnostics facilitate distinction between lethal and non-lethal subtypes of junctional epidermolysis bullosa: a case report and review of the literatureJürgen Bauer, Hauke Schumann, Karsten Sönnichsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cellsAnja Ulmer, Oleg Schmidt-Kittler, Jörg Fischer, et al.
Journal of the American Academy of Dermatology|January 31, 2006
Metastatic glucagonoma: treatment with liver transplantationPeter Radny, Thomas Kurt Eigentler, Karsten Soennichsen, et al.
Experimental Dermatology|June 26, 2003
Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanomaFriedegund Meier, Ulrich Caroli, Kapaettu Satyamoorthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategyClaus Garbe, Andrena Paul, Hanna Kohler-Späth, et al.
Pageof 2